Summary
CA 15-3 is a protein that can be raised in breast cancer, particularly advanced or metastatic disease. Its main role is in monitoring people with diagnosed breast cancer — tracking response to treatment and detecting recurrence — rather than screening or diagnosis, because it is often normal in early breast cancer and can be raised by benign conditions.
CA 15-3 reflects the activity of certain breast cancers and is most useful once a diagnosis has been made. In advanced or metastatic breast cancer, serial CA 15-3 levels help track how the cancer is responding to treatment — falling levels suggest response, rising levels suggest progression or recurrence.
It is not a screening or early-diagnosis test: CA 15-3 is frequently normal in early-stage breast cancer, and can be mildly raised in benign breast conditions, liver disease, and some other cancers. It is therefore always interpreted alongside imaging and the clinical picture.
CA 15-3 is closely related to another marker, CA 27.29, and both detect the same underlying protein (MUC1). The trend over time is more informative than any single measurement.
What It Is
CA 15-3 measures circulating fragments of MUC1, a large transmembrane mucin glycoprotein overexpressed and abnormally shed by many breast cancers. As tumour burden increases, more MUC1 enters the bloodstream, raising CA 15-3.
Because early or low-volume disease may release little MUC1, CA 15-3 is insensitive in early breast cancer and is not used for screening or initial diagnosis. Its value lies in monitoring advanced disease, where guidelines support its use alongside imaging and clinical assessment to track treatment response and detect recurrence.
Reference range: approximately < 30 U/mL, varying by laboratory. Mild elevations can occur in benign breast and liver conditions, so trends and context matter more than single values.
Functions
Treatment monitoring
Tracks response to treatment in advanced breast cancer — falling levels suggest the cancer is responding.
Recurrence detection
A rising CA 15-3 can signal recurrence or progression, prompting further imaging.
Disease burden indicator
Higher levels generally reflect greater tumour burden in metastatic breast cancer.
Trend tracking
Serial measurements over time are far more informative than a single result.
Reference Ranges
CA 15-3
Measured in U/mL| Status | Range (U/mL) | Range (kU/L) | What it means |
|---|---|---|---|
| Normal | < 30 | Within normal range — does not exclude breast cancer, especially early disease. | |
| Mildly raised | 30–50 | Mild elevation — may be benign; interpret with imaging and clinical context. | |
| Elevated | > 50 | Raised — significant mainly when monitoring known breast cancer; suggests greater tumour burden. |
CA 15-3 is not a screening or diagnostic test. It is often normal in early breast cancer and can be raised by benign conditions. Reference ranges vary by laboratory. The trend over time in known disease is what matters most.
Symptoms of Imbalance
CA 15-3 itself causes no symptoms; it is used to monitor known breast cancer rather than to detect symptoms.
- A normal CA 15-3 is reassuring but does not exclude breast cancer
- No symptoms from a low CA 15-3
- Symptoms of advanced or recurrent breast cancer
- Breast lump or change (with primary disease)
- Bone pain (bone metastases)
- Often no symptoms with mild benign elevation
Causes of Imbalance
- Normal in healthy people
- Effective treatment of breast cancer (falling CA 15-3)
- Early-stage breast cancer (often normal)
- Advanced or metastatic breast cancer
- Benign breast conditions (mild elevation)
- Liver disease
- Other cancers (lung, ovary, pancreas) in some cases
- Benign ovarian and inflammatory conditions
FAQs
No. CA 15-3 is not used for screening or early diagnosis because it is often normal in early-stage breast cancer and can be mildly raised by benign conditions. Breast cancer screening relies on mammography, and diagnosis on imaging and biopsy. CA 15-3 becomes useful after a diagnosis, mainly for monitoring advanced disease and response to treatment.
In someone with known breast cancer, a rising CA 15-3 can indicate that the cancer is progressing or has recurred, sometimes before symptoms or scan changes appear. It prompts further investigation with imaging. A single mildly raised value, however, is interpreted cautiously — benign conditions and laboratory variation can cause minor fluctuations, so the trend over time is what matters most.
CA 15-3 reflects the amount of tumour-derived MUC1 protein in the blood, which tends to be low when there is little cancer present. Early-stage and small breast cancers often release too little to raise the level, so CA 15-3 can be normal despite active disease. This is precisely why it is not used to detect or rule out early breast cancer.
Mild elevations of CA 15-3 can occur in benign breast conditions, liver disease, and some other cancers and inflammatory states. Because of this, a modestly raised CA 15-3 in someone without a cancer diagnosis is usually not alarming and is interpreted alongside the clinical picture and other investigations rather than in isolation.
References
- Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–5312. View source
- Duffy MJ, et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol. 2010;31(1):1–7. View source
- Molina R, et al. Tumor markers in breast cancer — European Group on Tumor Markers recommendations. Tumour Biol. 2005;26(6):281–293. View source